CareFusion's Home Spirometer and eDiary is EXACT-PRO Certified
CareFusion’s AM3 home spirometer and eDiary received EXACT-PRO Initiative certification last month.
The AM3 reads and saves relevant expiratory flow-volume parameters, such as PEF, FEV1, FVC and FEF, as well as recording symptoms, events, and medication, including severity and dose.
The eDiary guides patients through the process with instructions. Visual indicators, which the company refers to as a traffic light feature, allow immediate assessment of the measurement. The eDiary consists of flexible, programmable questionnaires embedded into a workflow: diary sessions can be controlled by independent time windows (e.g., morning/evening questions), audible and visual alerts, branching logic, and automated score calculation with immediate feedback to the patient.
Since it is intended for specific use in clinical studies, questions and instructions have been made available in many languages, including Kanji and Cyrillic character sets, making it appropriate for international trials.
The EXACT-PRO Initiative
A multi-sponsor initiative led to the introduction of a new patient reported outcome tool, EXACT-EXAcerbations of Chronic Pulmonary Disease Tool-because it was designed to standardize the method for evaluating acute exacerbations of COPD and chronic bronchitis (AECB).
Leading the project is Dr. Nancy Kline Leidy, Senior Vice President of Scientific Affairs for United BioSource Corporation, along with Dr. Terry Wilcox, Senior Research Scientist, and Senior Clinical Consultants, Drs. Paul Jones and Sanjay Sethi.
Patients use the 14-item per day diary on a personal digital assistant (PDA) that is meant to take less than three minutes to complete. This instrument has already been translated into 25 languages and there are presently other translations in progress.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
